TSS
MRNA icon

Two Sigma Securities’s Moderna MRNA Stock Holding History

Two Sigma Securities’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,326
Closed -$700K – 3385
2023
Q3 		$860K Sell
8,326
-3,575
-30% -$399K 0.01% 1151
2023
Q2 		$1.45M Sell
11,901
-38,525
-76% -$5.14M 0.02% 763
2023
Q1 		$7.74M Buy
50,426
+9,813
+24% +$1.62M 0.16% 144
2022
Q4 		$7.29M Sell
40,613
-6,428
-14% -$1.05M 0.22% 88
2022
Q3 		$5.56M Buy
47,041
+22,343
+90% +$3.39M 0.17% 129
2022
Q2 		$3.53M Sell
24,698
-10,495
-30% -$1.5M 0.13% 174
2022
Q1 		$6.06M Buy
35,193
+32,887
+1,426% +$5.54M 0.21% 96
2021
Q4 		$586K Sell
2,306
-675
-23% -$197K 0.03% 455
2021
Q3 		$1.15M Sell
2,981
-3,427
-53% -$1.26M 0.03% 445
2021
Q2 		$1.51M Buy
6,408
+3,813
+147% +$681K 0.05% 306
2021
Q1 		$340K Sell
2,595
-407
-14% -$59K 0.02% 392
2020
Q4 		$314K Buy
+3,002
New +$304K 0.01% 1004

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Two Sigma Securities's MRNA Position: Q4 2023 in Review

Two Sigma Securities sold out of Moderna (MRNA) in Q4 2023, closing a stake of 8,326 shares — an estimated $700K sold.

Two Sigma Securities first reported a position in MRNA in Q4 2020 and held it in 12 quarters. The position peaked at $7.74M in Q1 2023. 885 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Two Sigma Securities reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Two Sigma Securities sold 8,326 Moderna shares in Q4 2023, an estimated $700K.
  • Two Sigma Securities first reported a position in Moderna in Q4 2020 and held it in 12 quarters.
  • Two Sigma Securities's Moderna position peaked at $7.74M in Q1 2023.
  • 885 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Two Sigma Securities's 13F filing for Q4 2023, filed 14 Feb 2024.